Sunshine Biopharma Inc (SBFM) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sunshine Biopharma Inc $0.55, price $0.67, upside -17.0%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $0.6670 – $624,000 · fair‑value band $0.3651 – $0.6922 · the $0.6670 price screens above the $0.5536 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Sunshine Biopharma in your weekly email
Every Wednesday you see whether Sunshine Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
Show more
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Stock analysis
Sunshine Biopharma Inc (SBFM) currently trades at $0.6670, while our model-based Fair Value estimate is $0.5536, 17.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.3651 (bear) to $0.6922 (bull), the price of $0.6670 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sunshine Biopharma Inc reported revenue of $36.3M in FY2025 versus $228K in FY2021, a compound +255.1%/yr. Reported net income was −$6.0M in FY2025.
Key figures
Market cap $2.6M · P/S ratio 0.07 · EPS (TTM) $−9.16 · Net margin −16.5% · Return on equity −21.9% · Return on assets (EBIT) −38.3% · Operating margin −17.4% · Revenue (TTM) $35.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 97% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −17%, SBFM screens cheaper than that median.
Fair Value models
Bear $0.3651Fair Value $0.5536Bull $0.6922
Price $0.6670 · Upside -17.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+102.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+247.7%
Start year 2020 (pandemic). Over 10 years: +170.9% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+170.9%
’15
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−807.8% (2020) → −12.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside−17.0% · Below median
Profitability
Return on assets−9.9% · Bottom 25%
Net margin (TTM)−16.5% · Bottom 25%
Operating margin (TTM)−17.4% · Bottom 25%
Growth and dividend
Revenue growth−1.6% · Below median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sunshine Biopharma Inc (SBFM) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $0.5536 versus a price of $0.6670, about −17% upside (overvalued).
What is the fair value of SBFM?
Our model-based fair value for Sunshine Biopharma Inc is $0.5536 (as of Oct 4, 2026), built from audited fundamentals. The current price: $0.6670.
What is the quality score of SBFM?
Sunshine Biopharma Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sunshine Biopharma Inc (SBFM)?
Our model-based price target is the fair value of $0.5536 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario $0.3651, optimistic scenario $0.6922. It is a calculation from audited fundamentals, not an analyst target.
What is the Sunshine Biopharma Inc stock forecast for 2026?
Our models put fair value at $0.5536, about −17% upside versus a price of $0.6670 (overvalued). Cautious scenario $0.3651, optimistic scenario $0.6922. The calculation is refreshed regularly with new filings.
What is the revenue of Sunshine Biopharma Inc (SBFM)?
Sunshine Biopharma Inc reported trailing-twelve-month revenue of about $35.3M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Sunshine Biopharma Inc (SBFM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sunshine Biopharma Inc it is $0.5536 per share (as of Oct 4, 2026), against a price of $0.6670. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sunshine Biopharma Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, SBFM trades above its calculated fair value: price $0.6670, fair value $0.5536, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SBFM?
No. The price is what the market pays today ($0.6670); the fair value is what the company's own numbers justify ($0.5536). For Sunshine Biopharma Inc the two are $0.1134 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sunshine Biopharma Inc worth?
The market values Sunshine Biopharma Inc at about $2.6M (market capitalisation, as of Oct 4, 2026). Per share that is $0.6670; our models calculate a fair value of $0.5536 per share.
What do the bullish and bearish scenarios say about SBFM?
Our models span a range for Sunshine Biopharma Inc: cautious scenario $0.3651, base $0.5536, optimistic $0.6922 per share (as of Oct 4, 2026, price $0.6670). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sunshine Biopharma Inc (SBFM)?
Balance-sheet figures for Sunshine Biopharma Inc (as of Oct 4, 2026): return on equity −21.9%, debt of 0.08 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is SBFM from its 52-week high?
Sunshine Biopharma Inc trades at $0.6670, about 97% below its 52-week high of $22.00 and at the low of $0.6670 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5536 is for.
Which stocks are comparable to Sunshine Biopharma Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sunshine Biopharma Inc stock attractive at the current price?
The data as of Oct 4, 2026: price $0.6670, calculated fair value $0.5536 (−17%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SBFM calculated?
We run Sunshine Biopharma Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5536, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Sunshine Biopharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sunshine Biopharma Inc (SBFM)?
The closing price on Oct 2, 2026 was $0.6670. Our model-based fair value is $0.5536, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sunshine Biopharma Inc right now?
Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($0.3651 to $0.6922) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Sunshine Biopharma Inc
How large is the market capitalisation of Sunshine Biopharma Inc (SBFM)?
The market capitalisation of Sunshine Biopharma Inc is $2.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sunshine Biopharma Inc (SBFM)?
The price-to-sales ratio of Sunshine Biopharma Inc is 0.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sunshine Biopharma Inc (SBFM)?
Earnings per share at Sunshine Biopharma Inc are $−9.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sunshine Biopharma Inc (SBFM)?
The net margin of Sunshine Biopharma Inc is −16.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sunshine Biopharma Inc (SBFM)?
The return on equity (ROE) of Sunshine Biopharma Inc is −21.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sunshine Biopharma Inc (SBFM)?
On an EBIT basis the return on assets of Sunshine Biopharma Inc is −38.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sunshine Biopharma Inc (SBFM)?
The operating margin of Sunshine Biopharma Inc is −17.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sunshine Biopharma Inc (SBFM)?
Revenue at Sunshine Biopharma Inc is growing −1.6% versus a year earlier (3y avg +103%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sunshine Biopharma Inc (SBFM) generate?
The free cash flow of Sunshine Biopharma Inc is −$5.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sunshine Biopharma Inc (SBFM) hold?
Sunshine Biopharma Inc holds more cash than debt, $8.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sunshine Biopharma Inc in the live analysis
One click puts Sunshine Biopharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 4, 2026